A Look At Inspire Medical Systems (INSP) Valuation After Forecast Downgrades And Guidance Reset
Simply Wall St
Last updated: May 13, 2026
Inspire Medical Systems (INSP) has re-entered investor focus due to significant analyst revisions of revenue and earnings projections. This adjustment follows a first-quarter performance that transitioned from profit to a net loss, accompanied by a downward revision of the 2026 guidance. The company's stock experienced a notable decline after these announcements.
- Inspire Medical Systems reported a net loss of $38.2 million in the first quarter, a significant shift from the $1.1 million profit recorded in the same period last year. Revenue for the quarter was $97 million, showing a slight increase from $94.8 million year-over-year, but falling short of analyst expectations.
- The company revised its 2024 revenue guidance downwards to a range of $390 million to $400 million, compared to the previous forecast of $405 million to $420 million.
- The full-year earnings per share (EPS) guidance was also reduced to a range of -$1.10 to -$1.20, down from -$0.70 to -$0.80.
- Management attributed the challenges to lower-than-anticipated patient activations and increased sales infrastructure investments.
- Analysts have responded by cutting their price targets for INSP stock. For example, Truist Securities lowered its price target to $165 from $215, while maintaining a buy rating.
- Canaccord Genuity reduced its price target to $150 from $200, also keeping a buy rating.
- Piper Sandler also adjusted its price target to $157 from $204, maintaining an overweight rating.
- Despite the revised forecasts and stock price pressures, the company's long-term growth prospects in the sleep apnea market remain a key consideration for investors.
